Study of lung cancer regulatory network that involves erbB4 and tumor marker gene

Xuhui Ma, Lu Li*, Tongde Tian, Huaimin Liu, Qiujian Li, Qilong Gao

Department of Oncology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450008, China

Received 27 October 2016; revised 28 December 2016; accepted 7 January 2017
Available online 27 January 2017

KEYWORDS
Lung cancer; Tumor marker; ErbB4; Regulatory network

Abstract Our purpose is to screen out serum tumor markers closely correlated to the nature of solitary pulmonary nodule (SPN) and to draw a regulatory network containing genes correlated to lung cancer. Two hundred and sixty cases of SPN patients confirmed through pathological diagnosis were collected as subjects, factors closely correlated to the nature of SPN were screened out from eight tumor markers through Fisher discriminant method, and functional annotation and pathway analysis were conducted on erbB4 as well as its tumor marker genes by GO and KEGG databases. Four key tumor markers: CYFRA21-1, CA125, SCC-Ag and CA153 were successfully screened out and the first three proteins’ corresponding gene were KRT19, MUC16 and SERPINB3 while that of CA153 was not found. GO analysis on erbB4, KRT19, MUC16 and SERPINB3 showed that they covered three domains, cell components, molecular function and biological process; meanwhile, combined with KEGG database and based on signal pathway of erbB4, a regulatory network of lung cancer cells escaping from apoptosis was successfully made. This study indicates that serum tumor marker genes play an important role in the occurrence and development of lung cancer, besides, this study primarily discussed the molecular mechanism of these tumor markers in predicting tumor, which provides a basis for in-depth information about lung cancer.

1. Introduction
Lung cancer, a malignant tumor with highest morbidity and mortality currently, tops the five most common tumors’ list among males and ranks the second place among females, and it is still the top of the four cancers threatening people’s life according to 2015 cancer statistics report in China (Chen et al., 2016). And it is mainly because of the high misdiagnosis rate and missed diagnosis rate for early lung cancer. Expression of the early lung cancer usually is solitary pulmonary nodule (SPN) (Siegel et al., 2013), therefore, accurate discrimination of benign and malignant SPN is an effective method to reduce the mortality of lung cancer.

SPN is a roundlike solid lesion with a diameter no more than 3 cm. Data from American College of Chest Physicians (ACCP) show that among malignant SPN primary lung cancer accounts for 75%, and adenocarcinoma is the most common tumor followed by squamous cell carcinoma (Wahidi et al.,...
For patients with early primary lung cancer, their five-year survival rate will be up to 80% if they can be diagnosed early (Vazquez et al., 2009; Varoli et al., 2008); due to difficult qualification of SPN, about 50% lung cancer patients, however, miss optimal therapeutic time leaving them a relatively low five-year survival rate. Therefore, it is the key to distinguishing benign SPN from malignant SPN for secondary prevention of lung cancer, which still is a diagnostic difficulty.

CT imaging examination is the preferred approach for SPN identification, usually from nodule’s size, location, internal feature and surrounding environment. However, it’s not reliable to identify SPN only through imaging approach and laboratory diagnostic methods like tumor marker diagnosis is necessary. Tumor marker is chemical substance reflecting tumor’s existence and commonly used markers are carcino-embryonic antigen (CEA), carbohydrate antigen (CA) (like CA125, CA199 and CA153) and neuron-specific enolase (NSE). Reasonable usage of these markers will be helpful for early SPN diagnosis and treatment. Currently, however, there are few studies on inside molecular mechanism of these markers participating in lung cancer cell regulation. Our preliminary study analyzed the structural and functional changes of erbB4 before and after mutation (Chen and Zhao, 2016), and based on the original signal pathway of erbB4, tumor marker genes were added to the regulatory network in this study to uncover the internal molecular regulatory mechanism for prediction of tumor occurrence and development, which lays foundation for in-depth cancer suppressor research in the future.

2. Material and methods

2.1. Subjects

In this study, continuous data of patients who went to Affiliated Cancer Hospital of Zhengzhou University between 2012 and 2014 were collected. And through analysis of their medical records, 260 cases of SPN patients were selected including 145 cases of malignant SPN (according to the pathological diagnosis there were 88 cases of adenocarcinoma, 32 cases of squamous cell carcinoma, eight cases of adenosquamous carcinoma, two cases of nonsmall-cell lung cancer, four cases of neuroendocrine carcinoma, two cases of mucoepidermoid carcinoma, four cases of mucoepidermoid, one case of carcinoma mucocellular, one case of metastatic renal cell carcinoma, one case of metastasis breast cancer, one case of carcinoma sarcomatoides and one case of unclassified lung cancer) and 115 cases of benign PSN (56 cases of inflammation, 13 cases of tuberculosis, 14 cases of inflammatory pseudotumor, 11 cases of myotic infection, five cases of hamartoma, four cases of angioma, three cases of pulmonary abscess, two cases of epithelial tumor, one case of bronchiectasia, one case of glioma peripheral of chest wall, one case of lymphadenoma, one case of secondary osteogenic sarcoma of lung, one case of coccus infection, malignant dyskaryosis and one case of fibrocartilage). All above patients were confirmed by CT imaging diagnosis and pathological diagnosis.

2.2. Content measurement of serum tumor markers

In this study eight seismological indexes, including CEA, NSE, cytokeratin 19 fragment (CYFRA21-1), CA125, CA199, CA724, squamous cell carcinoma antigen (SCC-Ag) and CA153, in patients’ blood samples were detected. The detection of every index was in accordance with instruction on kit; CEA and CYFRA21-1 were detected by ELISA method; CA125, CA199, CA724, SCC-Ag and CA153 were detected by Roche E601 automatic immuno-analyzer and NSE was detected by radio immunoassay.

2.3. Methods

2.3.1. Fisher discriminant analysis

Fisher discriminant analysis was put in 1930s by British statistician Fisher who first defined Fisher discriminant analysis and applied it to discriminant analysis of iris, and this method has been improved continuously so till now it is still considered as one of the best feature extraction. Its fundamental idea is to conduct linear project on sample data making their between-class scatter maximum and within-class scatter minimum. Fisher discriminant method in SPSS 23.0 software was used to screen serologic tumor markers, aiming to screen out factors correlated to SPN nature.

2.3.2. GO analysis of genes correlated to lung cancer

Corresponding genes of tumor markers correlated to SPN nature were searched through literature search and AmiGo homepage (http://geneontology.org/) was visited to conduct Go analysis with screening condition being “Homo sapiens”. The screened out serum tumor markers and erbB4 were primarily analyzed and every gene was conducted functional annotation from cell components, molecular function and biological process, aiming to identify their functions and provide a basis for further researches.

2.3.3. KEGG analysis of genes correlated to lung cancer

After visiting KEGG database homepage (http://www.kegg.jp/kegg/pathway.html), key words “lung cancer” and “erbB4” were input to search signal pathway; literature search was used to find key factors running by corresponding genes of tumor markers, and starting from these key factors and based on the signal pathway of erbB4, all signal pathways were linked together through using key nodes, and functions of every tumor marker were added as well.

3. Results

3.1. CT imaging maps and histopathological slice of different pathological type SPN patients

Patients highly suspected as malignant SPN not only underwent CT examination but histopathological examination while the benign SPN patients only underwent histopathological examination. Figs. 1-3 respectively are CT imaging map and histopathological slice of lung adenocarcinoma, squamous cell carcinoma and inflammatory pseudotumor.

3.2. Content measurement of serum tumor markers

Measurement results of eight tumor markers for totally 260 patients in malignant SPN group and benign SPN group are listed in Table 1 and the eight tumor markers were CEA,
Figure 1  CT imaging map and histopathological slice of lung adenocarcinoma.

Figure 2  CT imaging map and histopathological slice of lung squamous cell carcinoma.

Figure 3  CT imaging map and histopathological slice of inflammatory pseudotumor.

Table 1  Measurement results of eight serum tumor markers of SPN patients.

| Serum tumor markers | Malignant SPN group   | Benign SPN group | t     | P   |
|---------------------|-----------------------|------------------|-------|-----|
| CEA (ng/mL)         | 14.61 ± 2.38*        | 3.23 ± 0.87      | 4.18  | 0.000|
| NSE (ng/mL)         | 15.01 ± 0.64*        | 12.03 ± 0.52     | 3.61  | 0.000|
| CYFRA21-1 (ng/mL)   | 7.25 ± 0.82*         | 2.18 ± 0.12      | 6.118 | 0.000|
| SCC-Ag (ng/mL)      | 2.04 ± 0.17*         | 1.06 ± 0.06      | 5.49  | 0.000|
| CA125 (U/mL)        | 49.65 ± 5.69*        | 19.65 ± 2.69     | 4.76  | 0.000|
| CA199 (U/mL)        | 26.34 ± 3.70*        | 16.86 ± 1.98     | 2.26  | 0.025|
| CA724 (U/mL)        | 6.27 ± 0.84          | 5.43 ± 2.59      | 0.34  | 0.736|
| CA153 (U/mL)        | 18.27 ± 1.34*        | 10.58 ± 0.79     | 4.95  | 0.000|

Note: * represents the difference is statistically significant compared to the benign group.
NSE, CYFRA21-1, CA125, CA199, CA724, SCC-Ag and CA153. Seen from the table, except CA724, all levels of other seven serum tumor markers in malignant SPN group were higher than that in benign SPN group (P < 0.05).

3.3. Screening results by Fisher discriminant analysis

According to clinical test results, CEA, NSE, CYFRA21-1, CA125, CA199, CA724, SCC-Ag and CA153 were regarded as variables included in discriminant analysis model. Wilks’ lambda method was employed to conduct a stepwise discriminative analysis for these variables with F value being discriminative statistics standard and totally four predictors with statistical significance were screened out which were CYFRA21-1, CA125, SCC-Ag and CA153 (see Tables 2 and 3).

3.4. GO and KEGG analysis of genes correlated to lung cancer

CYFRA21-1, CA125, CA199 and SCC-Ag were searched through databases like NCBI Database, Wanfang Database, VIP Database and CNKI Database, and so on. CYFRA21-1, a soluble fragment of cytokeratin 19 which is the expression product of KRT19 gene, is mainly applied for detection of tumor marker of non-small-cell lung cancer (Liu et al., 2015). CA125 and CA153 both are carbohydrate antigens. CA125 whose gene is MUC16 is the specific markers of ovarian cancer diagnosis and commonly used in lung cancer diagnosis (Homma et al., 2004); CA153 is the specific marker of breast cancer diagnosis but its genetic expression is still unclear based on current reports. SCC-Ag is squamous cell carcinoma antigen which is significant to non-small-cell lung cancer diagnosis, and two genes producing SCCA have been identified nowadays which are SCCA1 and SCCA2 and their homology in terms of amino acid level was 92% (Yan et al., 2011), and SCCA is the expression of SERPINB3 gene. ErbB4 also called HER4 gene is the fourth oncogene encoding human epidermal growth factor receptor and it was reported to be overexpressed in lung cancer tissues and to be correlative to lymph node metastasis, TNM staging and postoperative survival rate (Starr et al., 2006). KRT19, MUC16, SERPINB3 and erbB4 were input in the homepage of Amigo for their annotation in human.

The annotation of KRT19 gene is shown in Table 4 which indicates that KRT19 played an important role in cell component, molecular function and biological process and its protein products distributed in the central filament, the glycoprotein complex and the cell membrane, etc.; erbB4 has function of protein binding and muscle composition and cytoskeleton and is involved in many biological processes like Notch signaling pathway, embryonic cell differentiation, embryonic development and estrogen response. GO analysis results of MUC16 are listed in Table 5, and MUC16 gene mainly participates in cell component and biological process whose protein products can be seen in cell membrane and Golgi apparatus cavity and it plays a crucial role in multiple biological processes including cell adhesion, protein post-translational modifications and protein metabolism in cells, etc. The annotation of SERPINB3 gene is shown in Table 6, similarly, SERPINB3 is involved in cell components, molecular function and biological process. Specifically, the cell components contain the cytoplasm, the nucleus and cytoplasmic vesicle, etc.; molecular function covers activities of virus receptor, binding of protease, activity of serine-type and cysteine-type inhibitor; the biological processes include positive regulation of cell proliferation, regulation of endopeptidase activity, regulation of cell migration and negative regulation of proteolysis; what’s more, it participates in autocrine and paracrine process and penetration of virus into a host cell. Additionally, GO analysis outcomes of erbB4 gene are listed in Table 7 showing that erbB4 gene is involved in multiple functions, and its cell component includes nucleus, mitochondria and plasma membrane; its molecular functions contain protein tyrosine kinase activity, activation of protein tyrosine kinase receptor signal, epidermal growth factor receptor and ATP etc.; besides, it also participates in cell proliferation, ras protein signaling transduction, mitogen-activated protein kinases signaling pathway, transmembrane receptor protein tyrosine kinase signaling pathway, endothelial growth factor receptor signaling pathway and insulin receptor signaling pathway.

Inputting the keyword “erbB4” into KEGG signaling pathway database, explicit signaling pathway it participated in were found, and erbB4 was turned out to be involved in the signaling pathway of lung cancer cell escaping from apoptosis through PI3K → PKB/Akt → MDM2 → p53 while nothing about MUC16, SERPINB3 and KRT19 gene was found.

| Step | Entered | Wilks’ lambda Statistic df1 df2 df3 | Exact F Statistic df1 df2 | P |
|------|---------|-------------------------------------|--------------------------|---|
| 1    | CYFRA21-1 | .896 1 1 258.000 | 29.897 1 1 258.000 | 0.000 |
| 2    | SCC-Ag  | .811 2 1 258.000 | 30.039 2 2 257.000 | 0.000 |
| 3    | CA125 | .753 3 1 258.000 | 27.966 3 3 256.000 | 0.000 |
| 4    | CA125 | .726 4 1 258.000 | 24.068 4 4 255.000 | 0.000 |

Note: At each step, the variable that minimizes the overall Wilks’ lambda is entered.

a Maximum number of steps is 16.

b Minimum partial F to enter is 3.84.

c Maximum partial F to remove is 2.71.

d F level, tolerance, or VIN is insufficient for further computation.
And through gene annotation and literature search, these three genes were added to the signaling pathway of lung cancer cell escaping from apoptosis (see Fig. 4). According to the gene annotation, KRT19 is able to act on Notch signaling pathway. Besides, it’s reported (Gong, 2013) that MUC16 can enhance transportation of β-catenin which is the key effector molecule in Wnt signaling pathway from cytoplasm to nucleus, and it can activate Wnt signaling pathway and stimulate and enhance the expression of downstream oncogenes through interaction with β-catenin. As a tumor suppressor gene, the activation of p53 can cause cell apoptosis while its deactivation can help tumor’s development. Moreover, study by Molès found that p53 can inhibit KRT19’s expression (Molès et al., 1994). And SERPINB3 can act on β-catenin and TGFβ, which has influence on the growth and development of tumor (Turato et al., 2014).

4. Discussion

SNP is the unique roundlike solitary lesion whose diameter is less than 30 mm, and 150,000 cases of SNP are detected globally every year, among which 10–70% is malignant which is possible to develop into lung cancer anytime. Serological tumor marker is significant for determination of begin and malignant SPN, and the commonly used markers are CYFRA21-1, CA125, CA153 and SCC-Ag.

CYFRA21-1 known as cytokeratin 19-fragments is a soluble polypeptide and its principle of being a tumor-detection...
marker is that when apoptosis of tumor cells happens, the increasing of cytokeratins stimulated by activated protease will elevate patients’ CYFRA21-1 level in serum (Thomas et al., 2015). Currently, CYFRA21-1 is a top priority in detecting non-small-cell lung cancer. As for CA125, it not only is an ovarian cancer associated antigen but also has a high expression in serum of lung cancer patient, especially in lung adenocarcinoma patient. CA153 also is an important specific marker that can be used in detection of lung cancer (Ghosh et al., 2013). SCC-Ag, a squamous cell carcinoma antigen, exists in cytoplasm of squamous cell carcinoma of the uterus, lungs, cervix and head and neck, and is especially rich in non-keratinizing cancer cells. Chu et al. (2011) studied 805 patients with lung cancer and patients with benign lung diseases, even though the area under ROC of individual detection on lung cancer isn’t ideal, 37.3% patients with early stage lung cancer can be detected correctly through detection of SCC combined with other tumor markers, showing potential value of SCC in clinic application.

In this study four serological tumor markers which are significant for malignant and benign SPN detection were screened out through clinical cases, and the four markers are CYFRA21-1, CA125, CA153 and SCC-Ag. Then the corresponding genes of CYFRA21-1, CA125 and SCC-Ag respectively were identified as KRT19, MUC1 and SERPINB3 through literature search except CA153. Our previous research mainly studied the structures and function of erbB4 before and after its mutation and found that erbB4 expressed high in non-small-cell lung cancer (Kurppa et al., 2016) and that it’s closely correlated to the metastasis of cancer.

### Table 5 Results of GO analysis for MUC16 gene.

| Gene  | Gene/product name | Direct annotation | Ontology            | GO number |
|-------|-------------------|-------------------|---------------------|-----------|
| MUC16 | Mucin-16 (CA125)  | Integral component of membrane | Cellular_component | 0016021   |
|       |                    | Extracellular space | Cellular_component | 0005615   |
|       |                    | Plasmatic membrane  | Cellular_component | 0005886   |
|       |                    | Extracellular side of plasma membrane | Cellular_component | 0009897   |
|       |                    | Golgi lumen         | Cellular_component | 0005796   |
|       |                    | Extrinsic component of membrane | Cellular_component | 0019898   |
|       |                    | Vesicle             | Cellular_component | 0031982   |
|       |                    | Extracellular exosome | Cellular_component | 0070062   |
|       |                    | Protein O-linked glycosylation | Biological_process | 0006493   |
|       |                    | Cell adhesion       | Biological_process | 0007155   |
|       |                    | O-glycan processing | Biological_process | 0016266   |
|       |                    | Post-translation protein modification | Biological_process | 0043687   |
|       |                    | Cellular protein metabolic process | Biological_process | 0044267   |

### Table 6 Results of GO analysis for SERPINB3 gene.

| Gene  | Gene/product name | Direct annotation | Ontology                              | GO number |
|-------|-------------------|-------------------|---------------------------------------|-----------|
| SERPINB3 | SerpinB3 (SCCA)  | Extracellular space | Cellular_component                     | 0005615   |
|        |                   | Nucleus            | Cellular_component                     | 0005634   |
|        |                   | Cytoplasm          | Cellular_component                     | 0005737   |
|        |                   | Cytoplasmatic vesicle | Cellular_component                     | 0031410   |
|        |                   | Vesicle            | Cellular_component                     | 0031982   |
|        |                   | Extracellular exosome | Cellular_component                     | 0070062   |
|        |                   | Virus receptor activity | Molecular_function                    | 0001618   |
|        |                   | Protease binding   | Molecular_function                     | 0002020   |
|        |                   | Serine-type endopeptidase inhibitor activity | Molecular_function                   | 0004867   |
|        |                   | Cysteine-type endopeptidase inhibitor activity | Molecular_function                   | 0004869   |
|        |                   | Positive regulation of cell proliferation | Biological_process                  | 0008284   |
|        |                   | Negative regulation of peptidase activity | Biological_process                  | 0010466   |
|        |                   | Positive regulation of epithelial to mesenchymal transition | Biological_process                  | 0010718   |
|        |                   | Positive regulation of endopeptidase activity | Biological_process                  | 0010950   |
|        |                   | Negative regulation of endopeptidase activity | Biological_process                  | 0010951   |
|        |                   | Positive regulation of cell migration | Biological_process                  | 0030335   |
|        |                   | autocrine signaling | Biological_process                     | 0035425   |
|        |                   | Paracrine signaling | Biological_process                     | 0038001   |
|        |                   | Negative regulation of catalytic activity | Biological_process                  | 0043086   |
|        |                   | Negative regulation of JUN kinase activity | Biological_process                  | 0043508   |
|        |                   | Negative regulation of proteolysis | Biological_process                  | 0045861   |
|        |                   | Viral entry into host cell | Biological_process                   | 0046718   |
Table 7  Results of GO analysis for erbB4 gene.

| Gene         | Gene/product name                           | Direct annotation          | Ontology                  | GO number   |
|--------------|---------------------------------------------|----------------------------|----------------------------|-------------|
| erbB4        | Receptor tyrosine-protein kinase erbB4      | Extracellular region       | Cellular_component         | 0005576     |
|              | Nucleus                                     | Cellular_component         | 0005634                   |
|              | Nucleoplasm                                 | Cellular_component         | 0005654                   |
|              | Mitochondrion                               | Cellular_component         | 0005739                   |
|              | Mitochondrial matrix                        | Cellular_component         | 0005759                   |
|              | Cytosol                                     | Cellular_component         | 0005829                   |
|              | Plasma membrane                             | Cellular_component         | 0005886                   |
|              | Basolateral plasma membrane                 | Cellular_component         | 0016323                   |
|              | Receptor complex                            | Cellular_component         | 0043235                   |
|              | Integral component of membrane              | Cellular_component         | 0016021                   |
|              | Protein tyrosine kinase activity            | Molecular_function         | 0004713                   |
|              | Transmembrane receptor protein tyrosine kinase activity | Molecular_function | 0004714                   |
|              | Epidermal growth factor receptor binding    | Molecular_function         | 0005154                   |
|              | Protein binding                             | Molecular_function         | 0005515                   |
|              | Protein homodimerization activity           | Molecular_function         | 0042803                   |
|              | Transcription regulatory region DNA binding | Molecular_function         | 0044212                   |
|              | Receptor signaling protein tyrosine kinase activity | Molecular_function | 0004716                   |
|              | ATP binding                                 | Molecular_function         | 0005524                   |
|              | MAPK cascade                                | Biological_process         | 0000165                   |
|              | Activation of MAPKK activity                | Biological_process         | 0000186                   |
|              | Neural crest cell migration                 | Biological_process         | 0001755                   |
|              | Positive regulation of protein phosphorylation | Biological_process     | 0001934                   |
|              | Signal transduction                         | Biological_process         | 0007165                   |
|              | Transmembrane receptor protein tyrosine kinase signaling pathway | Biological_process | 0007169                   |
|              | Epidermal growth factor receptor signaling pathway | Biological_process     | 0007173                   |
|              | Small GTPase mediated signal transduction   | Biological_process         | 0007264                   |
|              | Ras protein signal transduction             | Biological_process         | 0007265                   |
|              | Nervous system development                  | Biological_process         | 0007399                   |
|              | Axon guidance                               | Biological_process         | 0007411                   |
|              | Heart development                           | Biological_process         | 0007507                   |
|              | Lactation                                   | Biological_process         | 0007595                   |
|              | Cell proliferation                          | Biological_process         | 0008283                   |
|              | Positive regulation of cell proliferation   | Biological_process         | 0008284                   |
|              | Negative regulation of cell proliferation   | Biological_process         | 0008285                   |
|              | Insulin receptor signaling pathway           | Biological_process         | 0008286                   |
|              | Fibroblast growth factor receptor signaling pathway | Biological_process | 0008543                   |
|              | Embryonic pattern specification             | Biological_process         | 0009880                   |
|              | Cell migration                              | Biological_process         | 0016477                   |
|              | Peptidyl-tyrosine phosphorylation           | Biological_process         | 0018108                   |
|              | Central nervous system morphogenesis        | Biological_process         | 0021551                   |
|              | Olfactory bulb interneuron differentiation   | Biological_process         | 0021889                   |
|              | Regulation of cell migration                | Biological_process         | 0030334                   |
|              | Fc-epsilon receptor signaling pathway        | Biological_process         | 0038095                   |
|              | Positive regulation of tyrosine phosphorylation of Stat5 protein | Biological_process | 0042523                   |
|              | Negative regulation of apoptotic process    | Biological_process         | 0043066                   |
|              | Positive regulation of phosphatidylinositol 3-kinase activity | Biological_process | 0043552                   |
|              | Mitochondrial fragmentation involved in apoptotic process | Biological_process | 0043653                   |
|              | Innate immune response                      | Biological_process         | 0045087                   |
|              | Positive regulation of transcription DNA-templated | Biological_process | 0045993                   |
|              | Protein autophosphorylation                 | Biological_process         | 0046777                   |
|              | Vascular endothelial growth factor receptor signaling pathway | Biological_process | 0048010                   |
|              | Neurotrophin TRK receptor signaling pathway  | Biological_process         | 0048011                   |
|              | Phosphatidylinositol-mediated signaling      | Biological_process         | 0048015                   |
|              | Positive regulation of cardiac muscle cell proliferation | Biological_process | 0060045                   |
|              | Mammary gland epithelial cell differentiation | Biological_process         | 006064        |
|              | Mammary gland alveolar development          | Biological_process         | 0060749                   |
|              | Cardiac muscle tissue regeneration          | Biological_process         | 0061026                   |
|              | Positive regulation of ERK1 and ERK2 cascade | Biological_process         | 0070374                   |
(continued on next page)
cells and to patients' prognosis, which indicates that erbB4 is a possible candidate of targeted molecular therapy (Starr et al., 2006). Therefore, this study conducted GO functional analysis and KEGG pathway analysis on KRT19, MUC16, SERPINB3 and erbB4, aiming to deeply explore the growth and development mechanism of lung cancer.

According to the GO analysis of KRT19, MUC16, SERPINB3 and erbB4, these four genes all cover three domains, cell component, molecular function and biological progress. For instance, KRT19 takes part in Notch signaling pathway, MUC16 is involved in protein translational modifications, SERPINB3 participates in cell proliferation and erbB4 takes part in Ras protein signaling transduction, mitogen-activated protein kinase (MAPK) signaling cascades and transmembrane receptor tyrosine kinase signaling pathway, and so on. At present, there are more full-fledged studies on erbB4 and it is known that erbB4 is involved in multiple signaling pathways and has explicit signaling pathway in KEGG pathway data base and it can help tumor cell escape from apoptosis through PI3K-Akt signaling pathway. Based on these current analyses, this study added KRT19, MUC16 and SERPINB3 to KEGG signaling pathway database through gene annotation and literature search and drew a signaling pathway on lung cancer cell escaping from apoptosis. As mentioned, KRT19 is involved in Notch signaling pathway and the cell surface receptor coded by the key gene Notch in this pathway plays an important role in the development of many biological cells. And it was reported that Notch signal has influence on cell proliferation, formation of cell borders, cell apoptosis and multipotent progenitor cell specialization, etc. Notch signaling pathway interacts with other key pathways, having significant influences on tumor's growth and development (Iso et al., 2003). Moreover, it's was reported that MUC16 and SERPINB3 both can act on the key factor β-catenin of Wnt signaling pathway (Gong, 2013; Molès et al., 1994; Turato et al., 2014). Wnt signaling pathway is an evolutionarily conserved signaling transduction pathway which also is important to control embryological development, and it contacts with other pathways through complicated networks. Aberrant activation of Wnt signaling pathway plays a crucial role in cell canceration, tumor growth and tumor invasion, thus any change of Wnt gene itself or its any member may induce tumor. In Wnt pathway, β-catenin plays an important role in it and was considered as the key hub, therefore, if it moves from cytoplasm to nucleus, it means that the signaling pathway has been activated and begins to perform its functions. Nowadays, it’s become a hot issue to regard Wnt signaling pathway as the target of gene therapy of tumor in scientific filed (Tai et al., 2015). On the other hand, SERPINB3 was reported to be able to act on TGFβ (Turato et al., 2014) which is a kind of cytokine with multiple biologic activities and it is involved in cell proliferation, differentiation and apoptosis. There has been a study indicating that TGFβ has very complicated influence on tumor. It can inhibit or improve tumor's development and metastasis by tumor microenvironment, for instance, during early stage of tumor TGFβ can inhibit cell proliferation and induce apoptosis, but if the tumor is in developing stage, TGFβ can promote tumor's development and metastasis through multiple mechanisms (Brian and Moses, 2006). p53 is a tumor suppressor gene (Meek, 2015) and was thought to be able to inhibit KRT19 expression in study of Molès et al. (1994). Mutant p53 gene can cause its original

| Gene | Gene/product name | Direct annotation | Ontology | GO number |
|------|-------------------|-------------------|----------|-----------|
|      | Positive regulation of STAT protein import into nucleus | Biological_process | 2000366  |
|      | Transcription, DNA-template | Biological_process | 0006351  |
|      | Positive regulation of phosphatidylinositol 3-kinase signaling | Biological_process | 0014068  |
|      | Cell fate commitment | Biological_process | 0045165  |
|      | Positive regulation of protein localization to cell surface | Biological_process | 2000010  |
|      | Negative regulation of neuron migration | Biological_process | 2001223  |
function loss which means it cannot regulate cell proliferation, growth or DNA repair thus it becomes an oncogene. Signaling pathway mediated by P53 gene plays a crucial role in regulating normal cell life activities and it has complicated connection with other signaling pathway inside cell, and p53 has been the most relevant gene to human tumors till now.

5. Conclusions

In this study, four serological tumor markers, CYFRA21-1, CA125, CA153 and SCC-Ag, related to SPN nature were screened out by Fisher discriminant method, and their corresponding genes were identified through literature search. And then correlative genes to lung cancer taking part in the regulatory pathway of lung cancer’s growth and development were analyzed by GO and KEGG analysis. Based on signaling pathway of erbB4, several tumor marker genes were supplied to draw a regulatory network of lung cancer cell escaping from apoptosis, which lays a foundation for supplement and improvement of lung cancer signaling pathway and curves out the way for cancer treatment targeting with oncogenes.

Acknowledgments

I thank all authors who have contributed to this paper for advice and comments and thank Affiliated Cancer Hospital of Zhengzhou University for providing research materials and experimental base. And this study is supported by the open cooperation project of Henan Province, China (Grant No. 132106000064) and by the Program of research in base open cooperation project of Henan Province, China (Grant No. 152300410151).

References

Brian, B., Moses, H.L., 2006. TGF-β: the molecular Jekyll and Hyde of cancer. Nat. Rev. Cancer 6, 506–520.
Chen, C.L., Zhao, J.W., 2016. Analysis of regulatory mechanism after ErbB4 gene mutation based on local modeling methodology. Genet. Mol. Res. 15.
Chen, W., Zheng, R., Baade, P.D., Zhang, S., Zeng, H., 2016. Cancer statistics in China, 2015. CA-Cancer J. Clin. 66, 115–132.
Chu, X.Y., Hou, X.B., Song, W.A., Xue, Z.Q., Wang, B., 2011. Diagnostic values of SCC, CEA, Cyfra2-1 and NSE for lung cancer in patients with suspicious pulmonary masses a single center analysis. Cancer Biol. Ther. 11, 995.
Ghosh, I., Bhattacharjee, D., Das, A.K., Chakrabarti, G., Dasgupta, A., 2013. Diagnostic role of tumour markers CEA, CA15-3, CA19-9 and CA125 in lung cancer. Indian J. Clin. Biochem. 28, 24–29.
Gong, Y.T., 2013. Preliminary study on MUC16 and its signaling pathway. Xiamen Univ., 1–59.
Homma, S., Satoh, H., Kagohashi, K., Fujiwara, M., Kamma, H., Sekizawa, K., 2004. Production of CA125 by human lung cancer cell lines. Clin. Exp. Med. 4, 139.
Iso, T., Kedes, L., Hamamori, Y., 2003. HES and HERP families: multiple effectors of the Notch signaling pathway. J. Cell. Physiol. 194, 237–255.
Kurppa, K.J., Denessiouk, K., Johnson, M.S., Elenius, K., 2016. Activating ERBB4 mutations in non-small cell lung cancer. Oncogene 35, 1283–1291.
Liu, Q.S., Yang, Z.H., Lu, X.B., Luo, Y., Jiao, Y., 2015. Value of serum CYFRA21-1, NSE, and ProGRP levels in diagnosis of primary lung cancer. Med. J. Natl. Defend Forces Southwest China 25, 954–957.
Meek, D.W., 2015. Regulation of the p53 response and its relationship to cancer. Biochem. J. 469, 325–346.
Moles, J.P., Schiller, J.T., Tesniere, A., Leigh, I.M., Guilhou, J.J., 1994. Analysis of HPV16 E6 and mutant p53-transfected keratinocytes in reconstituted epidermis suggests that wildtype p53 inhibits cytokeratin 19 expression. J. Cell Sci. 107, 435–441.
Siegel, R., Naishadham, D., Jemal, A., 2013. Cancer statistics, 2013. CA-Cancer J. Clin. 63, 11–30.
Starr, A., Greif, J., Vexler, A., Ashkenazy-Yoghera, M., Gladesh, V., Rubin, C., Kerber, G., Marmor, S., Lev-Ari, S., Inbar, M., Yarden, Y., Ben-Yosef, R., 2006. ErbB4 increases the proliferation potential of human lung cancer cells and its blockage can be used as a target for anti-cancer therapy. Int. J. Cancer 119, 269–274.
Tai, D., Wells, K., Arcaroli, J., Vanderbilt, C., Aisner, D.L., Messersmith, W.A., Ciem, C.H., 2015. Targeting the WNT signaling pathway in cancer therapeutics. Oncologist 20, 1189–1198.
Thomas, D.S., Fourkala, E.O., Apostolidou, S., Gunu, R., Ryan, A., 2015. Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. Br. J. Cancer 113, 268–274.
Turato, C., Vitale, A., Fasolato, S., Ruvoletto, M., Terrin, L., 2014. SERPINB3 is associated with TGFβ1 and cytoplasmic β-catenin expression in hepatocellular carcinomas with poor prognosis. Br. J. Cancer 110, 2708–2715.
Varoli, F., Vegardi, C., Caminiti, R., Francese, M., Gerosa, C., 2008. Management of solitary pulmonary nodule. Eur. J. Cardiothorac. Surg. 33, 461–465.
Vazquez, M., Carter, D., Brambilla, E., Gazdar, A., Noguchi, M., 2009. Solitary and multiple resected adenocarcinomas after CT screening for lung cancer: histopathologic features and their prognostic implications. Lung Cancer 64, 148–154.
Wahidi, M.M., Govert, J.A., Goudar, R.K., Gould, M.K., McCrory, D.C., 2007. Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer? ACCP evidence-based clinical practice guidelines (2nd edition). Chest 133, 948S–1078.
Yan, L.J., Zhao, X., Shao, S.L., 2011. Expression of SCCA1 and SCCA2 in cervical squamous cell carcinoma and its clinical significance. J. Shanxi Med. Univ. 42, 233–236.